Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-05-05

FDA Approved: SIMBRINZA — Supplemental Application (Alcon Laboratories, Inc.)

View source ↗

Summary

FDA approves a supplemental application for Simbrinza (brinzolamide/brimonidine tartrate) from Alcon Laboratories, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Simbrinza (brinzolamide/brimonidine)

Snippet

SUPPL AP for SIMBRINZA (BRINZOLAMIDE/BRIMONIDINE TARTRATE)